Genome-wide CRISPR Screening Identifies NFκB and c-MET as Druggable Targets to Sensitize Lenvatinib Treatment in Hepatocellular Carcinoma
Our results demonstrated that genome-wide CRISPR/Cas9 screening is a powerful tool for the design of rational combinational cancer therapy and provided candidate genes possible for combined treatments with lenvatinib to improve therapy efficacy.
Authors
- Zhijian Kuang
- Chun‐Ming Wong (ORCID: https://orcid.org/0000-0002-2497-7858)
- Cheng Li (ORCID: https://orcid.org/0000-0002-7201-9005)
- Jun Shen (ORCID: https://orcid.org/0000-0001-7206-1847)
- For-Fan Chan (ORCID: https://orcid.org/0000-0001-8078-0876)
- Cun Wang (ORCID: https://orcid.org/0000-0002-1403-8806)
- Wen-Sen Lai
- Carmen Chak-Lui Wong
- Wai Chin
- T.S.K. Wan
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Shanghai Cancer Institute (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Cellular and Molecular Gastroenterology and Hepatology
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.jcmgh.2025.101502
- Citations
- 2
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Research Grants Council, University Grants Committee
- University of Hong Kong
- Cornell Center for Materials Research
- Health and Medical Research Fund